i2o Therapeutics Names Kurt Graves Chairman and CEO, Announces Corporate Updates
Business Wire | August 28, 2023
i2o Therapeutics expands to new lab space at Lab Central’s 610 Main Street location
i2o Therapeutics | August 1, 2023
J&J, following in Sanofi’s footsteps, tasks i2o with oral delivery of large molecules
Fierce Pharma | January 10, 2022
Business Wire | January 6, 2022
iHarvard Startup Stories: Tyler Brown, i2O Therapeutics
Harvard Office of Technology Development | October 14, 2021
i2O Therapeutics Announces the Appointment of Kurt C. Graves as Executive Chairman
Business Wire | October 12, 2021
Business Wire | February 10, 2021
Business Wire | December 3, 2020
i2O Therapeutics named 2020 LaunchBio Boston Regional Finalist
LaunchBio | June 30, 2020
i2O Therapeutics Named Finalist in President’s Innovation Challenge
The Harvard Gazette | April 22, 2020
Injections to become pills, in vision of Harvard-launched startup
The Harvard Gazette | April 9, 2020
i2O Therapeutics Raises $4 million in Seed Funding Co-led by Sanofi Ventures and JDRF T1D Fund
Business Wire | April 9, 2020
i2o Therapeutics Presents at 2019 PODD Soapbox
The Conference Forum | October 8, 2019
i2o Therapeutics hits the ground running at Pagliuca Harvard Life Lab
Harvard Innovation Labs | October 1, 2019
‘Holy grail’ of insulin pill could end need for diabetics’ daily injections
The Independent | June 25, 2018
Insulin pill may be on the horizon for diabetics
The Guardian | June 25, 2018
Insulin pill instead of shot: How close are we for diabetes patients?
CNN | June 25, 2018